Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/2025-524172-29-00
2025-524172-29-00CompletedPhase 1

A Phase I, open-label, non-randomized study to assess the absorption, distribution, metabolism and excretion (ADME) and pharmacokinetics of LTP001 following a single oral dose of [14C]LTP001 in healthy male participants

Novartis Pharma AG1 site in 1 country6 target enrollmentStarted: March 17, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
6
Locations
1
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 64 years (18-64 Years)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Novartis Pharma Arzneimittel GmbH

Scientific

Novartis Pharma AG

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Phase 1
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
2023-510356-23-00Novartis Pharma AG76
Recruiting
Phase 1
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00Novartis Pharma AG27
Completed
Phase 1
A Phase 1, Open-label, Randomized, Crossover Study to Assess the Effect of Different Types of Co-administered Oral Liquids on the Relative Oral Bioavailability of a JNJ 77242113 Tablet Formulation in Healthy Participants.
2024-515230-32-00Janssen Cilag International16
Completed
Phase 1
Randomized, open-label clinical trial (Phase 1) to evaluate safety, tolerability, pharmacokinetics and food effects of a single dose of IM-250 in healthy volunteers
2024-518155-37-00Innovative Molecules GmbH24
Recruiting
Phase 1
Phase I, open-label study to evaluate the safety and immune activity of PeptiCRAd-1, an oncolytic virus coated with tumor-specific peptides in combination with the immunotherapy drug pembrolizumab in patients with injectable solid tumors in defined indicationsSarcomaColorectal cancerNon-small cell lung cancerMelanoma
2024-517580-23-00Valo Therapeutics Oy15